Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | AR | P10275 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21100519 | 0.78 | SLC6A4 (0.48) | SLC6A4KDM4EHSD17B10ARALDH1A1 | |
| SCHEMBL202010 | 0.77 | SLC6A4 (0.32) | SLC6A4 | |
| SCHEMBL333951 | 0.76 | SLC6A4 (0.47) | SLC6A4KDM4EHSD17B10ARALDH1A1 | |
| SCHEMBL13923556 | 0.76 | SLC6A4 (0.47) | SLC6A4KDM4EHSD17B10ARALDH1A1 | |
| SCHEMBL199651 | 0.75 | SLC6A4 (0.32) | SLC6A4 | |
| SCHEMBL3046643 | 0.74 | ALDH1A1 (0.58) | SLC6A4KDM4EHSD17B10ARALDH1A1 | |
| SCHEMBL2480563 | 0.74 | NR1H2 (0.50) | SLC6A4KDM4EHSD17B10ARALDH1A1 | |
| SCHEMBL518851 | 0.74 | ALDH1A1 (0.58) | KDM4EALDH1A1TDP1LMNAHTT | |
| SCHEMBL7937564 | 0.74 | SLC6A4 (0.45) | SLC6A4KDM4EHSD17B10ARALDH1A1 | |
| SCHEMBL2737144 | 0.74 | SLC6A4 (0.45) | SLC6A4KDM4EHSD17B10ARALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| US-6627714-B2 | Copolymerizing ethylene and dicyclopentadiene or tricyclopentadiene, and cyclic olefin in presence of metallocene catalyst to produce copolymer | MARUZEN PETROCHEMICAL CO., LTD. (JP) | 2003-09-30 | — | — | US | disclosed |
| US-20020058767-A1 | Method for producing an olefin type copolymer having a cyclic structure | MARUZEN PETROCHEMICAL CO., LTD. (JP) | 2002-05-16 | — | — | US | disclosed |
| EP-1205497-A2 | Method for producing an olefin type copolymer having a cyclic structure | MARUZEN PETROCHEMICAL CO., LTD. (JP) | 2002-05-15 | — | — | EP | disclosed |
| US-4069377-A | Polymerization of ethylenically unsaturated monomers employing secondary-aliphatic α-substituted azoalkanes | PENNWALT CORPORATION | 1978-01-17 | — | — | US | disclosed |
| US-4025502-A | POLYMERIZATION CATALYSTS, CURING AGENTS | PENNWALT CORPORATION (US) | 1977-05-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | SLC6A4 4191/4885KDM4E 4854/4885HSD17B10 467/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.